XML 63 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisition of Sangamo Therapeutics France S.A.S. (Tables)
 9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Summary of Estimated Fair Value of Net Assets Acquired
The following table summarizes the estimated consideration transferred and the fair value of the net assets acquired as of the Acquisition Date (in thousands):
 
October 1, 2018
Consideration transferred
$
45,911

Fair value of non-controlling interest
35,829

Fair value of TxCell
$
81,740

 
 
Cash
$
4,779

Current assets
2,427

Property and equipment
1,857

IPR&D
55,019

Other assets
155

Current liabilities
(9,761
)
Assumed debt liabilities
(4,933
)
Deferred tax liability, net
(6,798
)
Fair value of net identifiable assets acquired
42,745

Goodwill
38,995

Total fair value of net assets acquired
$
81,740
Summary of Non-controlling Interest
Non-controlling interest as of September 30, 2019 was as follows (in thousands):
Non-controlling interest at December 31, 2018
$
739

Fair value of additional shares acquired
(321
)
Loss attributable to non-controlling interest
(179
)
Non-controlling interest at September 30, 2019
$
239